NEW DELHI(NewsTimePro): Drug company Zids Cadilla has asked the Drug Controller General of India (DCGI) for permission to use the hepatitis drug pagedylated interferon olfa-2B in coronavirus infections. According to Zids Cadilla on Monday, the third phase of the pegylated interferon olfa-2 trial has been encouraging in the treatment of covid-infected people. According to the company, the company claims that the coronavirus is recovering quickly after its use in the coronavirus. The company, on the other hand, also claims that there is no side effect on the patient’s body after taking the medication. It is expected that the company will be allowed to use it in India after the company’s claim.
